EUVIMEDEUVIMED entdecken
Übersichtsarbeit

Convergent and Divergent Signaling Pathways in Cancer: A Dual-Axis Model for Adaptive Precision Oncology

Aliasgar Shahiwala PhD

ONCOLOGY · 2025

DOI: 10.46883/2025.25921052 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift ONCOLOGY, 2025. Verfasst von Aliasgar Shahiwala PhD. Hauptthemen laut MEDLINE: Antineoplastic Agents, Carcinogenesis, Neoplasms, Precision Medicine. Die Arbeit wurde bisher 2-mal zitiert (Crossref). Gefördert von: Swiss National Science Foundation.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Despite significant advances in cancer research, the complexity of signaling pathways remains a major challenge in precision oncology. Tumors harbor a diverse array of genetic alterations; however, these often converge onto a limited set of core signaling pathways, notably RAS/RAF/MEK/ERK (MAPK), PI3K/AKT/mTOR (PAM), and Wnt/β-catenin. Concurrently, these pathways diverge extensively downstream, driving therapeutic resistance through mechanisms such as epithelial-mesenchymal transition, immune evasion, and metabolic reprogramming. Unlike previous literature that largely provides descriptive accounts of pathway alterations, this review uniquely synthesizes convergent and divergent signaling into a clinically actionable diagnostic and therapeutic framework. It critically assesses current precision oncology strategies, identifies gaps, and proposes a dual-axis model that integrates static genomic profiling with dynamic signaling evolution to inform precision therapy. By highlighting opportunities for combination therapy informed by pathway interdependencies and adaptive resistance mechanisms, this perspective provides novel clinical insights and tangible directions for future research in overcoming resistance in cancer treatment.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antineoplastic AgentsCarcinogenesisNeoplasmsPrecision MedicineSignal TransductionHumansDrug Resistance, NeoplasmEpithelial-Mesenchymal TransitionGene Expression Regulation, NeoplasticMetabolic ReprogrammingMultiomicsOncogene ProteinsTumor EscapeTumor Suppressor Proteins

Substanzen

Antineoplastic AgentsOncogene ProteinsTumor Suppressor Proteins

Förderung

  • Swiss National Science Foundation

Zitieren

APA

Aliasgar Shahiwala PhD (2025). Convergent and Divergent Signaling Pathways in Cancer: A Dual-Axis Model for Adaptive Precision Oncology. ONCOLOGY. https://doi.org/10.46883/2025.25921052

Vancouver

Aliasgar Shahiwala PhD. Convergent and Divergent Signaling Pathways in Cancer: A Dual-Axis Model for Adaptive Precision Oncology. ONCOLOGY. 2025. doi:10.46883/2025.25921052

BibTeX
@article{AliasgarShahiwalaPhD2025,
  author = {Aliasgar Shahiwala PhD},
  title = {Convergent and Divergent Signaling Pathways in Cancer: A Dual-Axis Model for Adaptive Precision Oncology},
  journal = {ONCOLOGY},
  year = {2025},
  doi = {10.46883/2025.25921052}
}
Kostenlos starten →